Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | GPX4 | P36969 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25881972 | 0.87 | TSHR (0.50) | TSHRSLC6A3SLC6A4 | |
| SCHEMBL25983199 | 0.82 | TSHR (0.50) | TSHRSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21831116 | 0.80 | TSHR (0.48) | TSHRSLC6A3SLC6A2SLC6A4SLC6A9 | |
| SCHEMBL7067185 | 0.78 | TSHR (0.58) | TSHRSLC6A3SLC6A2SLC6A4MDM2 | |
| SCHEMBL6232174 | 0.78 | TSHR (0.58) | TSHRSLC6A3SLC6A2SLC6A4MDM2 | |
| SCHEMBL6231109 | 0.78 | TSHR (0.58) | TSHRSLC6A3SLC6A2SLC6A4MDM2 | |
| SCHEMBL2770710 | 0.76 | KMT2A (0.48) | TSHRSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL21831014 | 0.75 | MEN1 (0.47) | TSHRSLC6A9GPX4 | |
| SCHEMBL7959764 | 0.75 | TSHR (0.51) | TSHRSLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7973175 | 0.75 | TSHR (0.51) | TSHRSLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | TSHR 2365/4885SLC6A3 4255/4885SLC6A2 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.